Skip to main content

Advertisement

Table 2 Baseline characteristics of participants depending on the type intervention assigned*

From: Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease

  Standard intervention (n = 154) Intensive intervention (n = 146)
Women, n (%) 98(63.6) 92(63.0)
Men, n(%) 56(36.4) 54(37.0)
Age in years 58.6 ± 10.6 56.8 ± 10.6
Fibrinogen, mg/dl 368.7 ± 64.5 364.9 ± 59.4
Total cholesterol, mg/dl 210.2 ± 25.5 211.1 ± 26.7
Tryglicerides, mg/dl 116.6 ± 59.6 116.5 ± 54.3
cHDL, mg/dl 55.2 ± 13.1 54.2 ± 12.0
cLDL, mg/dl 134.3 ± 28.6 134.6 ± 26.9
Basal glucose, mg/dl 108.3 ± 33.1 108.5 ± 35.9
Hematocrit,% 42.0 ± 3.7 42.1 ± 3.4
Leucocytes, 10e12/l 7.6 ± 3.0 7.4 ± 2.0
Platelets, 10e9/l 243.0 ± 60.2 252.3 ± 67.6
Weight, kg 76.7 ± 12.9 75.7 ± 13.1
Height, cm 158.7 ± 8.4 158.7 ± 9.8
SBP, mmHg 134.7 ± 18.0 133.8 ± 17.4
DBP, mmHg 81.7 ± 9.4 80.7 ± 9.8
BMI, kg/m2 30.5 ± 5.1 30.3 ± 5.8
Obesity, (%) (55.5%) (46.8%)
Tobacco, (%) (26.8%) (31.9%)
Hipertensión arterial(%) (41.4%) (42.7%)
Diabetes mellitus(%) (15.1%) (11.9%)
HbA1c% in diabetic patients 6.9 ± (1.7) 7.1 ± (1.5)
  1. *The values represent mean ± standard deviation, except those in bold, representing number of patients (percentage)
  2. cHDL high density lipoprotein cholesterol,
  3. cLDL low density lipoprotein cholesterol;
  4. SBP systolic blood pressure;
  5. DBP diastolic blood pressure;
  6. BMI body mass index;
  7. HbA1C glycated haemoglobin